Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Back

HFA Premium Access

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Session: Rapid Fire 2 - Comorbodities

Topic: Cardiomyopathies

Speaker: Professor D. Adams (Le Kremlin-Bicetre Cedex, FR)

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Professor David Adams

Le Kremlin-Bicetre Cedex (France)

0 follower

9 more presentations in this session

Impact of Iron Deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.

Speaker: Doctor P. Martens (Genk, BE)

Heart failure and inflammation-related biomarkers as predictors of new onset diabetes in the general population

Speaker: Doctor N. Suthahar (Rotterdam, NL)

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- versus post-capillary pulmonary hypertension.

Speaker: Mr T. Gorter (Groningen, NL)

Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients

Speaker: Mr N. Grote Beverborg (Groningen, NL)

Circulating miRNAs as biomarkers for familial dilated cardiomyopathy

Speaker: Doctor D. De Gonzalo Calvo (Barcelona, ES)

Access

Abstract

Access the full session

Rapid Fire 2 - Comorbodities

Speakers: Professor D. Adams, Doctor P. Martens, Doctor N. Suthahar, Mr T. Gorter, Mr N. Grote Beverborg...

Access

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources